BACKGROUND: Despite universal vaccination, chronic hepatitis B virus (HBV) infection remains a public health concern in North America owing to immigration. We aimed to characterize the number of people with a positive result of testing for HBV surface antigen (HBsAg) in Calgary, a large urban Canadian health care region, and to assess whether recommended laboratory tests and specialist consultation were done for those identified as HBsAg-positive. METHODS: Based on laboratory and Alberta Health Services administrative data, we identified all adults (age > 18 yr) with a positive HBsAg test result from Jan. 1 to Dec. 31, 2014 within the Calgary Zone. Demographic and relevant laboratory data were extracted within 6 months of a positive HBsAg test result, and referral to hepatology (2011-2014) was identified from data on referral to a centralized clinic. Parametric and nonparametric statistical methods were used for analyses. RESULTS: We identified 1214 HBsAg-positive people (584 women [48.1%]; median age 44 [interquartile range (IQR) 36-55] yr). A total of 1192 people (98.2%) had alanine aminotransferase testing (median level 23 [IQR 16-34] U/L; 117 [9.8%] with elevated levels), 682 (56.2%) had testing for HBV DNA (median level 2.8 [IQR 2.1-3.8] logIU/mL), 630 (51.9%) had HBV e antigen testing (negative result in 548 [87.0%]), and 145 (11.9%) had HBV e antibody testing (positive result in 111 [76.6%]). Overall, 144 people (11.9%) received anti-HBV treatment, and 390 (32.1%) were referred to a hepatologist. INTERPRETATION: Many HBsAg-positive people in Calgary did not receive the recommended laboratory assessments. The results highlight the necessity of continual public health efforts to screen for chronic HBV infection in Canada and to ensure adequate follow-up in order to reach the World Health Organization's goal of viral hepatitis elimination by 2030. Copyright 2017, Joule Inc. or its licensors.
BACKGROUND: Despite universal vaccination, chronic hepatitis B virus (HBV) infection remains a public health concern in North America owing to immigration. We aimed to characterize the number of people with a positive result of testing for HBV surface antigen (HBsAg) in Calgary, a large urban Canadian health care region, and to assess whether recommended laboratory tests and specialist consultation were done for those identified as HBsAg-positive. METHODS: Based on laboratory and Alberta Health Services administrative data, we identified all adults (age > 18 yr) with a positive HBsAg test result from Jan. 1 to Dec. 31, 2014 within the Calgary Zone. Demographic and relevant laboratory data were extracted within 6 months of a positive HBsAg test result, and referral to hepatology (2011-2014) was identified from data on referral to a centralized clinic. Parametric and nonparametric statistical methods were used for analyses. RESULTS: We identified 1214 HBsAg-positive people (584 women [48.1%]; median age 44 [interquartile range (IQR) 36-55] yr). A total of 1192 people (98.2%) had alanine aminotransferase testing (median level 23 [IQR 16-34] U/L; 117 [9.8%] with elevated levels), 682 (56.2%) had testing for HBV DNA (median level 2.8 [IQR 2.1-3.8] logIU/mL), 630 (51.9%) had HBV e antigen testing (negative result in 548 [87.0%]), and 145 (11.9%) had HBV e antibody testing (positive result in 111 [76.6%]). Overall, 144 people (11.9%) received anti-HBV treatment, and 390 (32.1%) were referred to a hepatologist. INTERPRETATION: Many HBsAg-positive people in Calgary did not receive the recommended laboratory assessments. The results highlight the necessity of continual public health efforts to screen for chronic HBV infection in Canada and to ensure adequate follow-up in order to reach the World Health Organization's goal of viral hepatitis elimination by 2030. Copyright 2017, Joule Inc. or its licensors.
Authors: C Cohen; S D Holmberg; B J McMahon; J M Block; C L Brosgart; R G Gish; W T London; T M Block Journal: J Viral Hepat Date: 2010-12-08 Impact factor: 3.728
Authors: Marc G Ghany; Robert Perrillo; Ruosha Li; Steven H Belle; Harry L A Janssen; Norah A Terrault; Margaret C Shuhart; Daryl T-Y Lau; W Ray Kim; Michael W Fried; Richard K Sterling; Adrian M Di Bisceglie; Steven-Huy B Han; Lilia Milkova Ganova-Raeva; Kyong-Mi Chang; Anna Suk-Fong Lok Journal: Clin Gastroenterol Hepatol Date: 2014-07-08 Impact factor: 11.382
Authors: J P Villeneuve; M Desrochers; C Infante-Rivard; B Willems; G Raymond; M Bourcier; J Côté; G Richer Journal: Gastroenterology Date: 1994-04 Impact factor: 22.682
Authors: Jack X Q Pang; Scott Zimmer; Sophia Niu; Pam Crotty; Jenna Tracey; Faruq Pradhan; Abdel Aziz M Shaheen; Carla S Coffin; Steven J Heitman; Gilaad G Kaplan; Mark G Swain; Robert P Myers Journal: PLoS One Date: 2014-04-22 Impact factor: 3.240
Authors: Stephen Ip; Jo-Ann Ford; Kirby Lau; Vladimir Marquez; Marisa Guan; Carolyn Klassen; Jessica Chan; Wc Peter Kwan; Mel Krajden; Eric M Yoshida Journal: Can J Infect Dis Med Microbiol Date: 2015 Jul-Aug Impact factor: 2.471
Authors: Vinh D Vu; Ailinh Do; Nghia H Nguyen; Lily H Kim; Huy N Trinh; Huy A Nguyen; Khanh K Nguyen; My Nguyen; Andrew Huynh; Mindie H Nguyen Journal: BMJ Open Gastroenterol Date: 2015-10-21
Authors: Carla S Coffin; Alnoor Ramji; Curtis L Cooper; David Miles; Karen E Doucette; Philip Wong; Edward Tam; David K Wong; Alexander Wong; Sylvester Ukabam; Robert J Bailey; Keith Tsoi; Brian Conway; Lisa Barrett; Tomasz I Michalak; Stephen E Congly; Gerald Minuk; Kelly Kaita; Erin Kelly; Hin Hin Ko; Harry L A Janssen; Julia Uhanova; Brendan C Lethebe; Sarah Haylock-Jacobs; Mang M Ma; Carla Osiowy; Scott K Fung Journal: CMAJ Open Date: 2019-10-22
Authors: Carla Osiowy; Ken Swidinsky; Sarah Haylock-Jacobs; Matthew D Sadler; Scott Fung; David Wong; Gerald Y Minuk; Karen E Doucette; Philip Wong; Edward Tam; Curtis Cooper; Alnoor Ramji; Mang Ma; Carmine Nudo; Keith Tsoi; Carla S Coffin Journal: JHEP Rep Date: 2022-02-22
Authors: Eva van Oorschot; Özgür M Koc; Astrid Ml Oude Lashof; Inge Hm van Loo; Robin Ackens; Dirk Posthouwer; Ger H Koek Journal: J Virus Erad Date: 2022-06-20